Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin vs Dapagliflozin in Type 2 Diabetes
NCT04654390Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Change from Baseline in Hemoglobin A1c level at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04654390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654390.